Ratings Align Technology, Inc.

Equities

Real-time Estimate Cboe BZX Other stock markets 09:46:30 12/06/2025 pm IST			5-day change	1st Jan Change
181.80 ^USD	-1.99%		+0.82%	-12.84%

04/06	Align Technology, Inc. Presents at Jefferies Global Healthcare Conference 2025, Jun-04-2025 08:10 AM
28/05	Align Technology, Inc. Presents at Stifel Jaws & Paws Conference 2025, May-28-2025 08:00 AM

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Overall, and from a short-term perspective, the company presents an interesting fundamental situation.

Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
The group's high margin levels account for strong profits.
Thanks to a sound financial situation, the firm has significant leeway for investment.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Considering the small differences between the analysts' various estimates, the group's business visibility is good.

With a 2025 P/E ratio at 25.14 times the estimated earnings, the company operates at rather significant levels of earnings multiples.
In relation to the value of its tangible assets, the company's valuation appears relatively high.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
Over the past four months, analysts' average price target has been revised downwards significantly.

Source: Surperformance

Source: MSCI

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Fundamentals (Composite)	Global Valuation (Composite)	Financial estimates revisions (Composite)	Capi.($)
	ALIGN TECHNOLOGY, INC.				1.34TCr
	ABBOTT LABORATORIES				24TCr
	MEDTRONIC PLC				11TCr
	CENCORA, INC.				5.56TCr
	BECTON, DICKINSON AND COMPANY				4.95TCr
	HOYA CORPORATION				4.06TCr
	DEXCOM, INC.				3.25TCr
	TERUMO CORPORATION				2.7TCr
	STERIS PLC				2.37TCr
	SARTORIUS STEDIM BIOTECH				2.26TCr
	Average				6.13TCr
	Weighted average by Cap.